Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Lohith Gowda, Mithun Shah, Ifra Badar, Qaiser Bashir, Nina Shah, Krina Patel, Rashmi Kanagal-Shamanna, Rohtesh Mehta, Donna M. Weber, Hans C. Lee, Elisabet E. Manasanch, Abdul Shah, Sheeba K. Thomas, Simrit Parmar, Yago Nieto, Robert Z. Orlowski, Richard Champlin, Muzaffar H. Qazilbash

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.

Original languageEnglish (US)
Pages (from-to)1089-1093
Number of pages5
JournalBone marrow transplantation
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2019

ASJC Scopus subject areas

  • Hematology
  • Transplantation

MD Anderson CCSG core facilities

  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs'. Together they form a unique fingerprint.

Cite this